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 Type II diabetes mellitus (T2DM) has been associated with the onset of diet-induced 
obesity, which is currently on the rise worldwide. T2DM is typically characterized by insulin 
resistance in peripheral tissues such as adipose tissue, liver, and skeletal muscle. In skeletal 
muscle it is widely accepted that the defective insulin action is due to the inability of the cell to 
sufficiently activate the insulin signalling pathway and promote systemic glucose uptake. The 
sarcolipin-null (KO) mouse is a potential novel model for diet-induced obesity and diabetes. 
KO mice become significantly more obese and display a greater glucose intolerance than 
wildtype (WT) mice following an 8-week high-fat diet (HFD; 42% calories from fat) but the 
underlying mechanisms are still unknown.  
In this study the role of defective skeletal muscle insulin signalling in the development 
of the impaired glucose tolerance in KO mice was investigated. It was hypothesized that the 
HFD fed KO mice would exhibit greater reductions in IRS1 tyr
628
 and Akt ser
473
 
phosphorylation (i.e. decreased activation of the insulin signalling pathway) than controls. 
Furthermore, it was believed that KO mice would display increased phosphorylation of IRS1 
ser
307
, which is commonly associated with insulin resistance. At 16-weeks of age KO mice and 
littermates were subdivided into two groups and placed on either a HFD (n=30) or chow diet 
(n=24) for an 8-week period. Changes in body weight, glucose tolerance, and insulin tolerance 
were assessed pre- and post-diet period. Following the completion of the diet intervention mice 
were treated with an intraperitoneal injection of insulin (0.75U/kg) or vehicle solution and 
sacrificed for tissue collection. Epididymal/inguinal and retroperitoneal fat pads were removed 
for assessment of whole body adiposity. Whole gastrocnemius muscle was excised and 
homogenized for Western blot analysis of several key proteins of the insulin signalling 
cascade.  
Following completion of the HFD KO mice (48.6 ± 1.6 g) weighed significantly more 
than HFD fed wildtype (WT) mice (41.5 ± 1.6 g), and all chow fed mice (KO: 36.8 ± 1.5 g; 
WT: 35.2 ± 1.2 g; p<0.001). Glucose tolerance testing showed that KO mice exhibited 
significantly greater glucose intolerance compared to control mice post-HFD (p<0.001). 
Insulin tolerance testing, however, revealed no change in insulin sensitivity in KO or WT mice 
post-HFD (p>0.05). The HFD fed KO mice (0.73 ± 0.06 g) had an elevated retroperitoneal fat 
pad weight than HFD fed WT (0.49 ± 0.05 g) and all chow fed mice (KO: 0.28 ± 0.04 g; WT: 
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0.24 ± 0.04 g; p<0.01). Western blot analysis revealed a similar reduction in insulin receptor 
substrate-1 (IRS1) tyr
628
 phosphorylation in both KO and WT mice following the HFD (Con 
WT: 2.82 ± 0.69; Con KO: 3.06 ± 0.73; HFD WT: 1.71 ± 0.28; HFD KO: 1.28 ± 0.11 fold 
increase over non-insulin stimulated mice; p<0.02). IRS1 ser
307
 phosphorylation was elevated 
in both genotypes post-HFD (HFD WT: 2.97 ± 1.19; HFD KO: 2.17 ± 0.59 fold increase over 
standard chow fed control mice; p<0.03). Insulin treatment did not stimulate phosphorylation 
of Akt ser
473
 in KO or WT mice regardless of diet (p>0.05). In summary there was no 
difference between KO and WT mice in skeletal muscle insulin sensitivity as assessed by the 
phosphorylation of insulin signalling intermediates. An increase in IRS1 ser
307
 phosphorylation 
appears to be the primary mechanism for the reduced activation of IRS1 following the HFD in 
both KO and WT mice. However, the results from the current investigation did not support the 
notion that impaired skeletal muscle insulin signalling is responsible for the more pronounced 
diet-induced glucose intolerance observed in KO mice. Future studies investigating the 
viability of skeletal muscle GLUT4 translocation and glucose uptake as well as the glucose-
induced insulin secretion of pancreatic β-cells following consumption of a HFD would help 
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1.0 OBESITY & DIABETES 
1.1 Introduction to Obesity 
 Over the past 20 years the incidence of obesity has progressively increased and current 
evidence suggests that this epidemic will continue to escalate (Katzmarzyk & Mason, 2006). In 
Canada, recent estimates indicate that 35% of the nation’s population is classified as 
overweight while 15% is considered obese (Katzmarzyk & Mason, 2006), which is most likely 
a conservative estimate as self-reported measures typically underestimate the actual incidence 
of obesity (Rowland, 1990; Tjepkema, 2006; Merrill & Richardson, 2009). The high 
prevalence of obesity has translated into an annual estimated cost of $4.3 billion on the 
Canadian health care system (Katzmarzyk & Janssen, 2004).  
 The hallmark characteristic associated with obesity is an inappropriate fat accumulation 
primarily as a result of a chronic positive energy imbalance (Schrauwen, 2007) and typically 
diagnosed by an individual’s body mass index (BMI). BMI (body weight (kg) / height (m
2
)) is 
a common surrogate measure for percent body fat (Deurenberg et al., 2001) that is used to 
assess potential abnormalities in body composition as determined by the World Health 
Organization guidelines. One of the most accurate methods for determining differences in body 
composition, particularly in humans, is the use of the dual-energy x-ray absorptiometry 
technique (Mattsson & Thomas, 2006). 
 The development of coronary heart disease and stroke, hypertension, gall bladder 
disease, some types of cancer (breast, colon, and prostate), and respiratory dysfunction have all 
been strongly associated with increased adipose tissue mass and obesity (Flegal et al., 2007; 
Kopelman, 2007; Blakemore & Froguel, 2008). Obesity has also been found to be an 
independent risk factor for the development of type II diabetes (Must et al., 1999) as 80% of 
type II diabetics are obese (Bloomgarden, 2000). The presence of obesity appears to predispose 
individuals to an accumulation of lipid metabolites in insulin sensitive tissues and subsequent 
insulin resistance, which will be discussed in further detail in Section 3.0 Insulin Resistance 






1.2 Introduction to Diabetes 
Diabetes is a metabolic disorder characterized by the presence of hyperglycemia due to 
insufficient insulin release, defective insulin action, or both (Alberti & Zimmet, 1998). The 
most common form of diabetes is non-insulin dependent diabetes mellitus, otherwise referred 
to as type II diabetes mellitus (T2DM) or adult-onset diabetes (Alberti & Zimmet, 1998). The 
primary characteristic of T2DM is an inadequate response to insulin by the peripheral tissues 
such as skeletal muscle, adipose tissue, and the liver despite near normal levels of pancreatic 
insulin release (Alberti & Zimmet, 1998). Over time, insulin resistance can lead to a chronic 
elevation of the plasma glucose level, otherwise known as hyperglycemia (Alberti & Zimmet, 
1998; Karlsson & Zierath, 2007). 
 The International Diabetes Federation states that someone is diagnosed with diabetes 
every five seconds somewhere in the world (IDF, 2007). In 2000, the global prevalence of 
diabetes was estimated to be at 2.8% of the population, or 171 million people (Wild, Roglic, 
Green, Sicree, & King, 2004) which is significantly lower than the estimated incidence of 
T2DM in Canada (Lipscombe & Hux, 2007). It is projected that the worldwide prevalence will 
more than double to 366 million people by the year 2030 (Wild, Roglic, Green, Sicree, & King, 
2004). Diabetes is the fifth leading cause of death in developing countries worldwide (CDA, 
2008); diabetics experience a life expectancy that is 5-15 years less than healthy individuals 















Figure 2.1: Insulin Signaling Pathway in Skeletal Muscle (Cell Signaling, 2009) 
 
2.0 Insulin Signalling in Skeletal Muscle 
Skeletal muscle is the primary target of insulin-stimulated glucose uptake in diabetic 
and non-diabetic individuals (Shulman et al., 1990). In the classic study by DeFronzo et al. 
(1981), skeletal muscle accounted for 75% of exogenous glucose uptake during insulin 
infusion. The process by which insulin stimulates glucose uptake is a complex, multi-stepped 
process which ensures the tight regulation of plasma glucose levels. As seen in Figure 2.1, 
insulin elicits its effect on skeletal muscle through a series of phosphorylation processes that 
link the initial binding of insulin to the insulin receptor on the sarcolemma through the 
translocation of glucose transporters (GLUT) to the cell membrane surface and increase in 
glucose uptake into the cell (Krook, Wallberg-Henriksson, & Zierath, 2004).  
 
2.1 Insulin Receptor 
 Insulin receptors (IR) are found embedded in the cell membrane of all insulin 
responsive tissues such as adipose tissue, the liver, and skeletal muscle. The IR is composed of 
4 major peptide-subunits: 2 extracellular alpha-subunits of 135-kDa to which insulin can bind, 
and 2 intracellular 95-kDa beta-subunits (Borge et al., 2002). Upon insulin binding to the 
alpha-subunits, the tyrosine kinase domain on the beta-subunits of the IR exhibits 
autophosphorylation capabilities and rapidly phosphorylates several key tyrosine residues 




binding of several downstream signalling molecules including the insulin receptor substrates 
(Karlsson & Zierath, 2007). 
  
2.2 Insulin Receptor Substrate 
 Insulin receptor substrates (IRS-1 to 4) act as docking proteins for a variety of insulin 
responsive molecules and function as key mediators of the insulin signal. The tissue 
distribution and functional role of each IRS isoform varies throughout the body, however IRS 
recruitment occurs in a similar fashion. Each IRS protein contains a phosphotyrosine binding 
(PTB) domain that will bind to the phosphorylated tyrosine residues on the IR (Karlsson & 
Zierath, 2007). Upon IRS binding the kinase activity of the activated IR will phosphorylate 
several tyrosine residues within a tyrosine-methionine-X-methionine (YMXM) motif on IRS 
which activates the protein (Shoelson et al., 1992, Karlsson & Zierath, 2007). The 
phosphorylated YMXM motif provides a suitable docking site for downstream intermediates of 
the insulin signalling cascade containing src-homology 2 (SH2) domains, such as 
phosphatidylinositol 3-kinase (Sun et al., 1991; Shoelson et al., 1992; Karlsson & Zierath, 
2007). 
 In skeletal muscle IRS-1 and IRS-2 are the predominantly expressed isoforms of the 
protein involved in the regulation of glucose homeostasis. Determining the specific function of 
each IRS protein has proven difficult since the high sequence similarity and partial functional 
redundancy between the isoforms allow for potential compensations to occur. For instance, 
IRS-1 transgenic knockout mice exhibit only mild peripheral insulin resistance due to a 
compensatory up-regulation of IRS-3 (Kaburagi et al., 1997). Nonetheless, recent findings 
indicate that each protein has exclusive signalling roles. 
 In L6 myotubes, a reduction of either IRS-1 or IRS-2 by small interfereing RNA gene 
silencing revealed that IRS-1 mediates GLUT4 translocation and glucose uptake while IRS-2 
has no effect on these parameters (Huang et al., 2005). Furthermore, in heterozygous null 
rodents for the gene coding for either IR/IRS-1 or IR/IRS-2, the former develop severe insulin 
resistance in skeletal muscle while the latter show severe insulin resistance of the liver (Kido et 
al., 2000). Complete knockout of the IRS-2 gene in mice leads to the development of T2D 
primarily from a reduced pancreatic β-cell mass and insufficient insulin release even though 
moderate whole body insulin resistance is reported in the liver and skeletal muscle (Withers et 
5 
 
al., 1998). These results suggest that IRS-1 is the predominant isoform mediating signal 
transduction in skeletal muscle while IRS-2 is thought to be important in pancreatic β-cell 
development and hepatic signalling processes. In humans IRS-2 may have a slightly larger role 
in skeletal muscle insulin signalling than in rodent models since the human IRS-3 gene is non-
functional (Krook, Wallberg-Henriksson, & Zierath, 2004). 
 
2.3 Phosphatidylinositol 3-Kinase 
 Phosphatidylinositol 3-kinase (PI3K) is an essential intermediary protein in the insulin 
signalling pathway of glucose uptake (Krook, Wallberg-Henriksson, & Zierath, 2004). PI3K is 
composed of a 110-kDa catalytic subunit (p110) and one of several regulatory subunits (p85α, 
p85β, p55α, p50α, or p55γ). The most predominant regulatory subunit in insulin sensitive 
tissue is the p85α subunit which comprises 70-80% of the total regulatory subunits in these 
tissues (Ueki et al., 2002; Ueki et al., 2003). 
The regulatory subunit contains a SH2 domain that binds phosphorylated tyrosine 
residues with a high affinity (Karlsson & Zierath, 2007). Upon tyrosine phosphorylation of 
IRS, the regulatory subunit of PI3K binds to the activated IRS and the newly formed protein 
complex migrates towards the plasma membrane. Following migration, the p110 subunit 
phosphorylates the 3’-OH position of the inositol ring of plasma membrane inositol 
phospholipids converting phosphatidylinositol-3,4-bisphosphate (PI2P) to PI-3,4,5-
triphosphate (PI3P) (Karlsson & Zierath, 2007). The increase of plasma membrane PI3P 
initiates the recruitment of proteins containing pleckstrin homology domains to the cell surface 
such as protein kinase B/Akt and phosphoinositide-dependent kinase-1 (PDK1) (Leney & 
Tavare, 2009). 
 
2.4 Protein Kinase B/Akt 
 Protein kinase B, also known as Akt, is a serine/threonine kinase that has been found to 
be a central intermediate for several metabolic pathways downstream of PI3K such as in the 
activation of glycogen synthase kinase-3 (Karlsson & Zierath, 2007). Akt has also been shown 
to have a critical role in GLUT4 translocation and glucose transport in adipocytes and L6 
myotubes (Tanti et al., 1997).  
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 There are three isoforms of Akt found in skeletal muscle (Akt1, Akt2, and Akt3).  
Investigations utilizing isoform specific knockout models have revealed specialized functional 
roles for each isoform. From these studies, Akt2 deficiency leads to the development of insulin 
resistance and diabetes-like symptoms, and therefore appears to play an essential role in insulin 
signalling and glucose uptake (Cho et al., 2001a).  On the other hand, Akt1 was required for 
normal growth but did not have a significant influence on glucose homeostasis in mice (Cho et 
al., 2001b). 
One of the key features of Akt is that its N-terminus contains a pleckstrin homology 
domain that favours the binding of phosphatidylinositol lipids, such as PI3P. Thus, Akt will re-
localize to the cell membrane upon the production of PI3P by PI3K, which compartmentalizes 
the serine/threonine kinase to the area of insulin signalling.  (Karlsson & Zierath, 2007) 
Once anchored to the cell membrane through its interaction with PI3P, Akt undergoes 
two phosphorylation steps to reach complete activation (Alessi et al., 1996). First, Akt is 
phosphorylated on its C-terminus at Ser
473
 by mTOR:Rictor:GbL complex (Sarbassov et al., 
2005). Additionally, PDK1, which is allosterically activated by PI3P, phosphorylates the 
catalytic domain of Akt at Thr308 (Alessi et al., 1997; Krook, Wallberg-Henriksson, & 
Zierath, 2004). 
 
2.5 Akt Substrate of 160 kDa 
 It has been well established that insulin mediates the translocation of GLUT4 to the cell 
membrane and increases glucose uptake (Leney & Tavare, 2009); however, the exact 
mechanistic steps that link the activation of Akt to the recruitment of GLUT4 has remained 
elusive. Recently, Sano et al. (2003) reported the discovery of a novel insulin-activated Akt 
substrate of 160 kDa, subsequently named AS160. 
 AS160 was first implicated as a mediator of glucose uptake upon observations that 
point mutations at two or more of the phosphorylation sites on AS160 significantly reduced 
insulin-stimulated GLUT4 translocation (Sano et al., 2003). Additionally, reducing the content 
of AS160 in 3T3-L1 adipocytes causes a 2-fold increase in cell surface GLUT4 and glucose 
uptake without insulin stimulation (Gonzalez & McGraw, 2006). Karlsson et al. (2005) have 
also shown that insulin-stimulated AS160 phosphorylation is significantly reduced in skeletal 
muscle from T2D patients. 
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There are five potential sites of phosphorylation (3 serine and 2 threonine residues) on 
AS160 in response to insulin (Sano et al., 2003). AS160 also contains a GTPase activating 
protein (GAP) domain for a Rab (Sano et al., 2003). Rabs are small G proteins that are 
commonly cited to regulate many cellular processes involving vesicle formation, movement, 
and fusion (Zerial & McBride, 2001). More recently, Rabs 8A and 14 have been implicated in 
GLUT4 translocation in muscle and are regulated by the GAP domain of AS160 (Miinea et al., 
2005; Ishikura et al., 2007). 
Interestingly, Sano et al. (2003) also reported that insulin-stimulated GLUT4 
translocation was preserved following the point mutations of the phosphorylation sites of 
AS160 when an additional mutation within the GAP domain was present. This provides a 
strong indication that AS160 requires a functional GAP domain to inhibit glucose uptake. 
The proposed mechanism by which AS160 regulates GLUT translocation is quite 
interesting as the recruitment of AS160 differs from the other insulin signalling intermediates. 
Presumably the non-phosphorylated form of AS160 is considered to be the active structure and 
restricts GLUT translocation to the cell surface. It is proposed that a guanosine triphosphate 
(GTP)-bound Rab molecule is necessary for GLUT translocation. The activated GAP domain 
of the non-phosphorylated AS160 hydrolyses the Rab-GTP to GDP and prevents GLUT 
translocation (Cartee & Wojtaszewski, 2007). Insulin stimulation, and subsequent PI3K and 
Akt activation, inhibits the activity of the GAP domain through the phosphorylation of several 
serine/threonine residues on AS160 (Bruss et al., 2005; Cartee & Wojtaszewski, 2007). 
Inactivation of the AS160 GAP domain prevents the hydrolysis of the nearby GTP-bound Rab 
and GLUT translocation will occur. 
 
2.6 Glucose Transport 
Insulin has been established to stimulate an increase of glucose uptake in skeletal 
muscle and adipose tissue for over 50 years (Park & Johnson, 1955).  However, it was not until 
decades later that insulin was observed to promote the movement of a glucose transport system 
from intracellular stores to the plasma membrane (Cushman & Wardzala, 1980; Suzuki & 
Kono, 1980). 
 Glucose transporters (GLUT) are members of the facilitated diffusion carrier family, 
and assist glucose and other hexose sugars to cross a cellular membrane barrier along a 
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concentration gradient (Mueckler, 1994; Augustin, 2010). There are fourteen members of the 
GLUT family (1-14) which have a wide distribution of expression throughout the body 
(Mueckler, 1994; Augustin, 2010). 
 In skeletal muscle two GLUT transporters, namely GLUT1 and GLUT4, are the 
primary transporters responsible for glucose uptake (Mueckler, 1994; Augustin, 2010). GLUT1 
is permanently expressed at low levels within the plasma membrane of skeletal muscle, where 
it supplies the cell with sufficient levels of glucose for basal cellular processes (Mueckler, 
1994; Augustin, 2010). GLUT4 is recognized as the primary glucose transporter isoform 
responsible for the enhanced glucose uptake following insulin stimulation (Charron et al., 
1989; Fukomoto et al., 1989; James et al., 1989). During the basal cellular state less than 5% of 
the total GLUT4 pool is found on the plasma membrane whereas up to 50% of the total 
GLUT4 pool can be found embedded in the cell surface following insulin stimulation (Leney 
& Tavare, 2009). 
 The majority of the work characterizing the location of the intracellular GLUT4 stores 
has been performed on 3T3-L1 adipocytes thereby questioning the applicability of the findings 
in vivo. Nonetheless, GLUT4 vesicles have been observed to be situated throughout subcellular 
portions of the cytoplasm and the perinuclear region of the cell, as well as in sections near the 
plasma membrane indicating that GLUT4 vesicles are localized to several distinct intracellular 
pools within the cell (Bornemann et al., 1992; Leney & Tavare, 2009).  
 The insulin-stimulated increase of GLUT4 vesicles from intracellular pools to the 
plasma membrane can be explained by two plausible models: the dynamic and the static model 
of GLUT translocation (Fig. 2.2). In the dynamic model of GLUT4 translocation, the total pool 
of GLUT4 vesicles are thought to be continuously cycling between the intracellular 
compartments and the plasma membrane. During basal cellular conditions a slow, steady state 
of GLUT4 exocytosis and endocytosis is achieved which ensures a constant rate of glucose 
uptake and maintenance of plasma glucose homeostasis (Leney & Tavare, 2009). Insulin 
stimulation increases the rate of GLUT4 exocytosis in order to increase the number of GLUT4 
molecules on the plasma membrane (Leney & Tavare, 2009). 
 The static model of GLUT4 translocation proposes that under basal conditions there are 
a limited number of GLUT4 vesicles available to cycle between the cell surface and 




recruits additional GLUT4 vesicles into the cycling pool from the intracellular stores thereby 
increasing the total number of GLUT4 vesicles available to fuse with the plasma membrane 
and increase the rate of glucose uptake (Leney & Tavare, 2009).  
 In either case it is believed that insulin elicits its action through the insulin signalling 
cascade and subsequent inactivation of AS160 (Larance et al., 2005). The active form of 
AS160 is thought to be bound to the GLUT4 storage vesicles (GSV) under basal conditions. 
Deactivation of the Rab GAP domain upon insulin stimulation leads to the dissociation of 
AS160 from the GSV which allows the translocation of GLUT4 to the cell surface.   
In the absence of insulin, GLUT4 vesicles located near the cell surface unsuccessfully 
attempt to bind to the plasma membrane (Bai et al., 2007). The dissociation of AS160 from the 
GLUT4 vesicle enables the GTP form of Rab to bind to the vesicle. The Rab-GTP complex 
will bind to Rip11 and provide a docking site on the GSV that will interact with acidic 
phospholipids in the plasma membrane (Bai et al., 2007; Leney & Tavare, 2009). GLUT4 is 
incorporated into the plasma membrane following the docking of the GSV which increases 
glucose uptake into the cell.  








3.0 Introduction to Insulin Resistance in Skeletal Muscle 
 One of the early events in the development of T2DM is the inability of insulin to 
promote peripheral glucose disposal into skeletal muscle and suppress hepatic production 
(Warram et al., 1990; Lillioja et al., 1993; Boden, 2001; DPPRG, 2005; Timmers, Schrauwen, 
& de Vogel, 2007). Insulin resistance has been well established to be associated with obesity as 
lean non-diabetic individuals are approximately two times more insulin sensitive than obese 
non-diabetics (Damsbo et al., 1991; Ferrannini et al., 1997; Boden, 2001). 
Originally it was believed that the impairment within skeletal muscle was due to a 
reduced capacity of hexokinase or glycogen synthase activity since an approximate 50% 
decrease in insulin-stimulated muscle glycogen synthesis is observed for T2DM (Shulman et 
al., 1990). However, it has since been reported that a reduction in the insulin-stimulated 
glucose transport appears to be the primary malfunction in the insulin signalling system and the 
cause for the onset of hyperglycemia (Cline et al., 1999; Cline et al., 2002; Fueger et al., 2004).  
There is a strong inverse correlation between insulin sensitivity and body fat mass as 
sensitivity decreases with weight gain and normalizes with reductions in fat mass (Sims et al., 
1973; Boden et al., 1993; Boden, 2001). Lipid infusion studies have revealed a close 
association between elevated plasma non-esterfied fatty acids (NEFAs) and impaired insulin 
sensitivity (Boden et al., 1991; Perseghin et al., 1997; Itani et al. 2002), and can produce 
defects in insulin-stimulated glucose transport due to the reduced tyrosine phosphorylation of 
IRS-1 (Boden & Chen, 1995; Dresner et al., 1999; Yu et al., 2002). Additionally, lowering 
chronically elevated plasma NEFAs with the anti-lipolytic drug Acipimox in obese non-
diabetic and obese diabetic individuals (both with impaired insulin sensitivity compared to lean 
controls) doubled insulin sensitivity in both groups (Santomauro et al., 1999). Taken together 
these results suggest a possible role of excess NEFAs in the onset of insulin resistance. 
The plasma NEFA hypothesis does fit the obesity-induced diabetes model as elevated 
plasma NEFA levels are common characteristics of obesity and insulin resistance (Gorden, 
1960; Reaven et al., 1988; Boden, 1997). However, in the lipid infusion studies there is a 3-4 
hour delay between the acute elevation of plasma NEFAs and the onset of insulin resistance; 
the insulin resistance also persists hours after the lipid infusion has stopped (Boden et al., 1991; 
Boden, 2001; Itani et al. 2002). Interestingly, changes in plasma NEFAs are linearly correlated 
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to intramuscular triglyceride (IMTG) levels and insulin resistance (Boden, 2001). Boden et al. 
(2001) have demonstrated that there is a dose-dependent increase in IMTG content following 
an acute elevation of plasma NEFA.  The elevated IMTG was measured 4-hours after lipid 
infusion suggesting that plasma NEFA may need to be transported into skeletal muscle and re-
esterified before insulin sensitivity is affected (Boden et al., 2001). 
 
3.1 Intramuscular Lipid Accumulation 
There has been a growing body of evidence for the role of aberrant lipid accumulation, 
particularly IMTG, in the onset of skeletal muscle insulin resistance (Shulman, 2000; Schmitz-
Peiffer, 2000). High-fat diet (HFD) fed mice exhibit symptoms of insulin resistance with an 
associated increase of IMTG content (Kraegen et al., 1991; Oakes et al., 1997; Dobbins et al., 
2001) whereas reducing IMTG content through caloric restriction improved insulin sensitivity 
in T2DM patients (Lara-Castro et al., 2008). 
However, not all insulin resistance is associated with elevated IMTG indicating that 
IMTG content cannot be the sole culprit in the onset of insulin resistance (Befroy et al., 2007). 
For example, the upregulation of the triglyceride synthesis enzyme diacylglyceride transferase- 
1 (DGAT1) in mice increases IMTG content but improves muscle insulin sensitivity (Liu et al., 
2007). Moreover, moderate intensity endurance exercise in humans increases DGAT1 
expression and IMTG content while improving insulin sensitivity (Phillips et al., 1996; Schenk 
& Horowitz, 2007). Interestingly, highly-trained elite endurance athletes have been found to 
exhibit severely elevated IMTG measures while exhibiting increased insulin sensitivity 
(Goodpaster et al., 2001; Kiens, 2006).  Thus, it appears that IMTG content is merely 
associated with the degree of insulin resistance rather than directly causing insulin resistance. 
More likely, specific IMTG lipid intermediates such as long chain acyl-CoA fatty acids 
(LCACoAs), ceramides, & diacylglycerides (DAGs) elicit a direct, negative impact on the 
insulin signalling cascade and impair glucose uptake as depicted in Figure 3.1 (Shulman, 2000; 






Figure 3.1: Proposed Mechanism of Insulin Resistance in Skeletal Muscle (Morino, Petersen, 
& Shulman, 2006) 
 
3.1.1 Long chain acyl-CoA 
 Typically, LCACoAs are transported into the mitochondria for energy production 
(Timmers, Schrauwen, & de Vogel, 2007). LCACoAs have also been shown to modify 
hexokinase activity (Timmers, Schrauwen, & de Vogel, 2007), and allosterically activate 
several protein kinase-C (PKC) isozymes (Orellana et al., 1990; Nesher & Boneh, 1994). The 
activation of PKC suggests a plausible mechanism linking the elevation of LCACoA to the 
onset of insulin resistance as PKC has been shown to interfere with the insulin signalling 
pathway (Ellis et al., 2000; Thompson et al., 2000; Morino, Petersen, & Shulman, 2006). 
Similarly, decreasing the LCACoAs concentration in skeletal muscle through dietary 
restrictions improves insulin sensitivity (Oakes et al., 1997). However, LCACoAs may solely 
be a marker of insulin resistance (as suggested with IMTG content) as LCACoA content is 
closely associated with increased intramuscular ceramide & DAG content (Timmers, 





 The de novo synthesis of ceramides is dependent upon 4 regulated enzymatic steps 
commencing with the rate-limiting condensation reaction of serine and palmitoyl-CoA by 
serine palmitolytransferase (Merrill, 2002; Timmers, Schrauwen, & de Vogel, 2007). 
Ceramides are common signalling molecules within a cell which mediate various processes 
such as inhibition of cell division and stimulation of apoptosis (Timmers, Schrauwen, & de 
Vogel, 2007). Elevated ceramide concentrations have been associated with skeletal muscle 
insulin resistance in animal models and men at high risk for developing T2DM (Turinsky, 
O’Sullican, & Bayly, 1990; Adams et al., 2004; Straczkowski et al., 2007), and with fatty acid 
induced insulin resistance in vitro in cell culture studies (Pickersgill et al., 2007; Sabin et al., 
2007). In contrast, inhibtion of de novo ceramide synthesis in Zucker diabetic fatty rats 
improved insulin sensitivity and lowered the associated ceramide concentration in skeletal 
muscle (Holland et al., 2007b). Ceramides elicit their effects downstream of IRS1 by 
promoting the dephosphorylation of Akt by protein phosphatase 2A (Dobrowsky et al., 1993; 
Schmitz-Peiffer, Craig, & Biden, 1999; Stratford et al., 2004; Holland et al., 2007a) which 
prevents the translocation of Akt from the cytoplasm to the plasma membrane (Stratford et al., 
2004). Thus, insulin-stimulated glucose transport is reduced. Inhibition of de novo ceramide 
synthesis restores Akt activation and subsequent glucose uptake following insulin stimulation 
(Chavez et al., 2003; Holland et al., 2007a). 
 
3.1.3 Diacylglycerides 
 As previously discussed with ceramides, DAGs are a common secondary messenger 
molecule within cells (Timmers, Schrauwen, & de Vogel, 2007). However, elevated levels of 
DAGs within muscle from acute lipid infusion or high-fat diets are associated with insulin 
resistance (Morino, Petersen, & Shulman, 2006; Timmers, Schrauwen, & de Vogel, 2007). 
Increasing intramuscular DAG content by inhibiting its primary catabolic enzyme (i.e. DAG 
kinase) results in impaired insulin signalling and glucose uptake, and mild obesity (Chibalin et 
al., 2008). There are several different reactions that produce DAGs; however, in models of 
lipid-induced insulin resistance the primary source of the elevated intramuscular DAG 
concentration is proposed to originate from the esterification of two LCACoAs with glycerol-
3-phosphate, and from the hydrolysis of triacylcerides (TAGs) (Timmers, Schrauwen, & de 
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Vogel, 2007). It is believed that DAGs transmit their effects on the insulin signalling cascade 
by activating the serine/threonine kinase, protein kinase C-θ (PKCθ) (Chalkey et al., 1998; 
Schmitz-Peiffer, 2000; Morino, Petersen, & Shulman, 2006). 
 
3.1.4 Protein Kinase-Cθ 
 Protein kinase-C (PKC) is a common component of cell functions such as cell 
proliferation, transmembrane ion transport, smooth muscle contraction, and glucose and lipid 
metabolism (Schmitz-Peiffer, 2000). However, PKCθ is regarded as the primary isozyme in 
skeletal muscle insulin resistance (Donnelly et al., 1994; Griffin et al., 1999) as aberrant PKCθ 
activation has been consistently shown to occur in conjunction with an accumulation of 
intramuscular lipids and insulin resistance (Morino, Petersen, & Shulman, 2006). PKCθ has 
also been shown to be associated with T2DM (Itani et al., 2001). Furthermore, PKCθ-null mice 
have been shown to be resistant to diet-induced insulin resistance (Kim et al., 2004). 
Nevertheless, other PKC isoforms may have a role in insulin resistance, particularly in humans, 
as PKCβ-II and PKCδ have been implicated in the acute onset of lipid-induced insulin 
resistance in skeletal muscle (Itani et al., 2002). 
 Lipid-induced activation of PKCθ promotes the translocation of PKCθ from the cytosol 
towards the cell membrane where it elicits its effect on the upstream insulin signalling 
molecules such as the IR and IRS (Ravichandran et al., 2000; Schmitz-Peiffer, 2000; Morino, 
Petersen, & Shulman, 2006). PKCθ phosphorylates serine (ser) residues on the β-subunit of the 
IR which prevents phosphorylation of tyrosine residues and subsequent docking of IRS due to 
conformational changes of the IR (Karasik et al., 1990; Paz et al., 1997; Aguirre et al., 2002; 
Liu et al., 2004).  









 have been implicated in insulin resistance in 
both humans and rodent models (Hirosumi et al., 2002; Kim et al., 2004; Morino et al., 2005; 
Morino, Petersen, & Shulman, 2006). Likewise, serine phosphorylation of IRS-1 leads to the 
dissociation of IRS-1 from PI3K, and prevents downstream activation of the insulin signalling 
pathway (Morino, Petersen, & Shulman, 2006). 







 to alanine residues on IRS-1 in mice defended against diet induced insulin resistance by 
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maintaining PI3K and Akt activation. This study showcased the crucial role that PKCθ 
expression and serine phosphorylation of the upstream insulin signalling molecules have on 
insulin sensitivity and glucose transport. 
 
3.2 Mitochondrial Dysfunction 
 The accumulation of intramyocellular lipids has previously been suggested to occur due 
to a decrease in the mitochondria mediated β-oxidation of fatty acids (Morino, Petersen, & 
Shulman, 2006; Kraegen & Cooney, 2008). Several studies have documented a reduction in 
mitochondria function following a prolonged high-fat diet (Sparks et al., 2005; Bonnard et al., 
2008). Other studies have reported a reduced mitochondria content in skeletal muscle from 
T2DM patients and their insulin resistant offspring (Petersen et al., 2004; Morino et al., 2005; 
Ritov et al., 2005). However, these cross-sectional observations of T2DM patients cannot 
decipher whether the decreased mitochondria content is a cause or consequence of the insulin 
resistance. Furthermore, more recent observations reveal that insulin resistance is clearly 
evident prior to a reduction in mitochondrial content (Park et al., 2005; Bonnard et al., 2008). 
 Turner et al. (2007) have shown that feeding mice a high-fat diet induces the increased 
expression of several mitochondrial oxidative enzymes and the fatty acid oxidative capacity of 
the mitochondria. Similarly, Hancock et al. (2008) demonstrated that high-fat feeding in rats 
produced a gradual increase in skeletal muscle mitochondria content which coincided with the 
onset of insulin resistance. The increased mitochondrial content was attributed to the observed 
upregulation of peroxisome proliferator-activated receptor (PPAR)-δ and subsequent increase 
in PPAR coactivator-1α (PGC-1α) (Hancock et al., 2008). Presumably the increased capacity 
of the mitochondria for β-oxidation is insufficient to prevent the accumulation of intramuscular 
lipids. 
It is evident that consistency is lacking in regards to the mitochondrial oxidative 
capacity in models of obesity and insulin resistance (Glatz, Luiken, & Bonen, 2010). Fatty acid 
oxidation can be either reduced (Bandyopadhyay et al., 2006; Han et al., 2007; Ouwens et al., 
2007), unaltered (Young et al., 2002; Smith et al., 2007), or increased (Turcotte et al., 2001; 
Coort et al., 2004a; Carley & Severson, 2005; Carley et al., 2007) in various rodent models of 
obesity or insulin resistance. The conflicting evidence in the literature suggests that there are 
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potentially other contributing factors to the lipid accumulation that is observed in insulin 
resistance. 
  
3.3 Elevated Free-Fatty Acid Transport in Skeletal Muscle 
 In healthy individuals, plasma NEFAs are transported into skeletal muscle due to an 
insulin- or contraction-mediated translocation of fatty acid transporters (CD36) from 
intracellular depots to the plasma membrane surface (Glatz, Luiken, & Bonen, 2010). 
Moreover, under basal conditions there is typically a steady distribution of CD36 fatty acid 
tranporters and GLUT4 transporters embedded in the cell membrane, and stored intracellularly 
(Glatz, Luiken, & Bonen, 2010). 
 In models of insulin resistance there is a notable shift in the rate of fatty acid uptake 
into cardiac and skeletal muscle (Chabowski et al., 2006; Glatz, Luiken, & Bonen, 2010). For 
instance, the rate of fatty acid transport into skeletal muscle is elevated by 40-80% in both 
high-fat fed and obese Zucker rats (Luiken et al., 2001; Hegarty et al., 2002) while a 4-fold 
increase is noted in obese human subjects (Bonen et al., 2004). Interestingly, the increased rate 
of lipid transport cannot be explained by an upregulation of fatty acid transporter expression as 
there are no changes in the total content of CD36 or any other fatty acid transport protein in 
skeletal muscle (Luiken et al., 2001; Han et al., 2007). There is, however, an increase in the 
number of CD36 transporters located on the plasma membrane in obese skeletal muscle 
indicating a permanent relocation of the transporters from the intracellular depots to the cell 
surface (Luiken et al., 2001; Bonen et al., 2004; Han et al., 2007). This increased membrane 
expression of CD36 highly correlates to the increased rate of fatty acid transport in the skeletal 
muscle from both obese animal models and human subjects (Bonen et al., 2004; Holloway et 
al., 2009).  
 It appears evident that the permanent relocation of CD36 to the plasma membrane has a 
significant role in the accumulation of intramyocellular lipids and subsequent onset of insulin 
resistance (Fig. 3.2). The rates of lipid transport, esterification, and oxidation are increased in 
skeletal muscle from obese Zucker rats (Holloway et al., 2009); however, the rate of 
esterification was 8-fold greater than that of lipid oxidation when expressed relative to fatty 
acid transport which indicates the rate of transport exceeds the cell’s capacity to oxidize the 




fatty acid uptake in insulin resistant tissue from high-fat fed rats and obese Zucker rats lowered 
the elevated rate of fatty acid esterification (Ploug et al., 1993; Coort et al., 2004a). Also, the 
elevated CD36-mediated fatty acid uptake has been observed prior to any changes in glucose 
uptake or onset of insulin resistance in cardiac myocytes from obese Zucker rats (Coort et al., 
2004b; Chabowski et al., 2006). Taken together these results support the notion that the 
accumulation of intramyocellular lipids is attributed to the relocation of CD36 transporters to 
the plasma membrane and the subsequent increase in fatty acid transport into the skeletal 
muscle cell. 
Figure 3.2: Substrate transport in healthy and diabetic individuals. In healthy individuals there 
is a balance between glucose and NEFA uptake (top). In a diabetic state (bottom) it is proposed 
that there is an increase in the number of CD36 transporters embedded in the plasma 
membrane leading to an elevated rate of NEFA transport into the skeletal muscle cell (Glatz, 








4.0 Rodent Obesity and Diabetes Models 
 The study of the progression of diabetes has been propelled over the past quarter of a 
century thanks in part to the discovery of several experimental rodent models that 
spontaneously portray common characteristics observed in human diabetes mellitus patients.  
Most notably the Otsuka Long-Evans Tokushima fatty rats, ob/ob mice, db/db mice, and 
Zucker Diabetic fatty rats exhibit moderate to severe obesity, hyperglycaemia, 
hyperinsulinemia, insulin resistance, deficient glucose stimulated insulin secretion, and 
reduced glucose transporter translocation in a comparable disease progression as in humans 
(Dubuc, 1976, Coleman, 1980; Coleman, 1982; Kawano et al., 1992; Kawano et al., 1994; 
Etgen & Oldham, 2000; Chen & Wang, 2005). However, these rodent models are not without 
limitations. For instance, one drawback of the ob/ob mouse is that the mutation of the leptin 
gene and subsequent lack of leptin production is not representative of the disease in the 
majority of humans since humans typically are hyperleptinemic and leptin resistant (Baribault, 
2010). Diet-induced obesity in the C57BL/6J mouse strain is another common model that 
produces an intermediate susceptibility to diabetes-related symptoms such as hyperglycemia, 
hyperinsulemia, and fatty liver; however, the later stages of the disease such as pancreatic islet 
















5.0 Introduction to Sarcolipin 
5.1 Sarcolipin Mouse Model 
 A potential novel mouse model for obesity and diabetes mellitus has been proposed by 
our laboratory (Sayer et al., 2008). The sarcolipin (SLN) knockout mouse (Babu et al., 2007a) 
has been shown to significantly gain more weight and adiposity than littermate control mice 
following an 8-week high fat diet (Sayer et al., 2008). Further, the KO mice became 
hyperglycaemic and hyperinsulinemic, and have elevated plasma levels of leptin, non-esterfied 
fatty acids, and cholesterol (Bal et al., 2009). Both the KO and the wild-type control groups 
displayed glucose intolerance and insulin resistance following the high-fat diet intervention; 
however, surprisingly the KO mice exhibited a more severely impaired response to glucose 
than the control mice during a 2-hour glucose tolerance test; however, HFD fed KO mice 
exhibited a comparable reduction in insulin sensitivity as HFD fed controls (Sayer et al., 2008; 
Bal et al., 2009). The KO mouse model appears to follow the usual disease progression of type 
II diabetes mellitus as all of these symptoms are typically associated with the disease (Reaven, 
1995; Alberti & Zimmet, 1998; Baribault, 2010). However, the origin of the glucose 
intolerance is currently unknown as SLN is not proposed to directly influence glucose uptake.  
 
5.2 Role of Sarcolipin in Skeletal Muscle 
 SLN is a 31-amino acid integral membrane protein that is found in abundance in the 
atria and moderately in slow-twitch musculature, such as the diaphragm or soleus muscle, in 
rodent tissue (Babu et al., 2007b). In larger mammals, such as rabbits and dogs, SLN protein 
levels are greater in both slow and fast twitch muscle compared to levels observed in the atria 
suggesting that SLN may assert a more significant role in skeletal muscle function in larger 
mammals (Babu et al., 2007b).  
SLN is closely associated with the sarco/endoplasmic reticulum calcium-ATPase 
(SERCA) within the sarcoplasmic reticulum membrane of atria and skeletal muscle cells 
(Wawrzynow et al., 1992; Asahi et al., 2002; Babu et al., 2007b). SERCA proteins (110 kDa) 
are well known Ca
2+
 pumps that transport Ca
2+
 ions across a membrane against a gradient 
(>10
4
-fold) in response to ATP hydrolysis thereby maintaining the basal cytosolic Ca
2+
 
concentration in skeletal muscle near 100 nM (Toyoshima, 2008). During repetitive exercise 
(i.e. muscle contractions) SERCA rapidly resequesters large amounts of Ca
2+








 transport ability of SERCA is regulated by SLN through a physical interaction 
between the two membrane-bound proteins (Asahi et al., 2002; Asahi et al., 2003). Asahi et al. 





 transport of both primary skeletal muscle isoforms of SERCA (1a and 2a) at all Ca
2+
 
concentrations under physiological conditions in HEK-293 cells as indicated from the 
rightward shift of the calcium concentration curve in Figure 5.1. Despite the decreased 
accumulation of Ca
2+
 in reconstituted SR vesicles, the presence of SLN has no effect on the 
rate of Ca
2+
-ATPase activity (Smith et al., 2002). Similarly, analyses of isolated soleus muscles 
from KO mice have also revealed that SLN uncouples ATP hydrolysis from Ca
2+
 transport 
(Bombardier et al., 2008).  
Figure 5.1: Effect of SLN on SERCA Ca
2+










5.3 Sarcolipin and Disease 
It is speculated that the diet-induced glucose intolerance observed in the KO mice 
develops as an indirect consequence of a chronic positive energy imbalance and the 
development of obesity. SERCA accounts for approximately 50% of the resting energy 
requirements of skeletal muscle (Norris et al., 2009) which suggests that SERCA has a 
significant role in daily whole body energy expenditure (Zurlo et al., 1990; Rolfe & Brown, 
1997; Levine, 2003). Not surprisingly, lowering the efficiency of the SERCA pump in soleus 
muscle through the uncoupling activity of SLN results in a 10% greater energy consumption of 
SERCA in wildtype muscle compared to KO muscle (unpublished results). Even a small 
variation in total daily whole body energy expenditure, such as altering the contribution of 
SERCA, can impose serious consequences on weight gain and health indicators as evidenced 









6.0 Purpose of Study 
6.1 Rationale for Study 
 The purpose of this study is to examine the effects of high fat feeding on the insulin 
signalling cascade in skeletal muscle from KO mice. As noted previously, after completion of 
an 8-week high-fat diet intervention, the KO mice become more obese and have more 
pronounced glucose intolerance than wild-type littermates (Sayer et al., 2008; Bal et al., 2009). 
However, the mechanisms involved remain to be established. 
 Insulin resistance is a common feature of diet-induced obesity (Shulman, 2000; Morino, 
Petersen, & Shulman, 2006). Moreover, results from whole body glucose tolerance testing 
generally correlate well with the results from the euglycemic-hyperinsulinemic clamp 
technique (Bergman et al., 1987; Bergman, 1989), which is the gold standard for the 
assessment of insulin resistance (DeFronzo, Tobin, & Andres, 1979). Therefore, it is 
reasonable to expect that the KO mice would exhibit a noticeably greater degree of peripheral 
insulin resistance. As previously discussed, insulin resistance is the result of an insufficient 
insulin-stimulated glucose uptake (Timmers, Schrauwen, & de Vogel, 2007). Generally, a 
breakdown in the insulin signalling cascade is the primary reason for the decreased glucose 
transport in models of diet-induced obesity and diabetes. Thus, this study examined the extent 
of diet-induced impairment of the insulin signalling cascade in the KO mice. More specifically, 
IRS1 tyr
628
 and Akt ser
473
 phosphorylation will be assessed as markers for the degree of insulin 
signalling pathway activation as previous described (Fujii et al., 2004; Morino et al., 2008; 
Mullen et al., 2009). Further, changes in IRS1 ser
307
 phosphorylation will be examined in an 
attempt to characterize a plausible mechanism for potential post-HFD decreases in IRS1 
activation. The information provided from this study will help to characterize the KO mouse as 
a potential model of severe diet-induced obesity and diabetes. 
 
6.2 Brief Description of Experimental Approach 
 The euglycemic-hyperinsulinemic clamp is the most accurate method to assess insulin 
resistance quantitatively (DeFronzo, Tobin, & Andres, 1979). However, it is quite difficult to 
perform in mice, and has a high associated cost to perform the testing procedure. This study 
proposed to assess the insulin signalling pathway in skeletal muscle through the analysis of 
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several key phosphorylation sites on signalling proteins of the insulin cascade of glucose 
uptake. Numerous studies have utilized antibodies for the specific phosphorylation sites and to 
quantify the amount of each protein by Western blot techniques (Fujii et al., 2004; Morino et 
al., 2008; Mullen et al., 2009). 
 
6.3 Specific Objectives 
 There are several key objectives associated with the present investigation. The goal(s) 
of the study were to: 
a) Assess the effects of an 8-week high-fat diet on whole body and fat pad weight(s) in 
KO and wildtype mice; 
b)  Evaluate potential differences in the glucose handling capability of the KO and 
wildtype mice by means of a 2-hour glucose tolerance test following the high-fat diet 
intervention; 
c) Utilize an intraperitoneal insulin bolus to examine the insulin sensitivity of both mouse 
genotypes during a 2-hour insulin tolerance test; 
d) Examine the effects of SLN ablation on insulin-stimulated tyr628 phosphorylation of 
IRS1 and ser
473
 phosphorylation of Akt following the high-fat diet; 
e) Compare the degree of ser307 phosphorylation of IRS1 after the completion of the high-
fat diet in KO and wildtype mice. 
 
6.4 Hypotheses 
Following the 8-week high-fat diet the KO mice will: 
a) Gain more weight and become more obese compared to control mice; 
b) Exhibit a greater intolerance to glucose compared to control mice as assessed by a 
glucose tolerance test; 
c) Show no significant differences in whole body insulin sensitivity compared to control 
mice fed the high-fat diet as assessed by an insulin tolerance test; 
d) Demonstrate a significant reduction of insulin-stimulated tyr628 phosphorylation of 
IRS1 and ser
473 
phosphorylation of Akt compared to control mice; 
e) Display a greater level of ser307 phosphorylation of the IRS1 molecule compared to 




7.1 Animal Colonies 
 A sarcolipin knockout mouse model (KO) was donated by Dr. Muthu Periasamy from 
Ohio State University to establish a viable mouse colony. Breeding pairs for the colony were 
born from cross-breeding KO mice with C57BL mice, thus generating heterozygous KO mice. 
The heterozygous KO mice were bred producing homozygous wild type (WT, +/+), 
heterozygous (HET, +/-), and homozygous-null (KO, -/-) mice. 
 Genotyping of mice was performed on extracted DNA from 4 week old mice using a 
Genomic DNA mini kit (Invitrogen). The DNA of interest was amplified by RT-PCR and 
imaged using a bio-imaging system (Syngene). Briefly, 50 ng of extracted DNA was added to a 
Taq DNA polymerase mix (Fermentas: 3mM MgCl2, 200 µM dNTP, & 1u of Taq DNA 
polymerase) and 0.4 µM each of the appropriate 5’ and 3’ genomic primers (SLN-WT, 
forward, 5’-TGT CCT CAT CAC CGT TCT CCT-3’and reverse 5’-GCT GGA GCA TCT 
TGG CTA ATC-3’; KO, Forward, 5’- GTG GCC AGA GCT TTC CAA TA-3’and reverse 5’-
CAA AAC CAA ATT AAG GGC CA-3’).  Samples were placed in a thermal cycler (MJ 
MINI, BIO-RAD) and denatured  for 3 minutes at 94°C followed by 30 cycles of denaturation 
for 30 sec at 94°C, annealing for 30 sec at 54°C, and extension for 60 sec at 72°C, this 
followed by a final extension at 72°C for 7 min. The amplified products were then separated on 
a 1% agrose gel containing 0.01% ethidium bromide (BioShop) and identified using a bio-
imaging system and densitometric analysis which was performed using the GeneSnap software 
(Syngene). 
 
7.2 Experimental Protocol 
 Fifty-four age-matched animals (27 WT; 27 KO) were individually housed in an 
environmentally controlled room on a 12:12hr light/dark cycle for the duration of the twelve 
week study period. Prior to the intervention period all of the experimental animals were fed a 
standard chow diet (60% of calories from carbohydrate, 5% of calories from fat; Tekland 22/5 
Rodent Diet, Harland-Tekland, Madison, WI) and water ad libitum. Further, all animals 




 At approximately 16 weeks of age the animals were sub-divided into two groups where 
one group was fed a high-fat diet (42% of calories from fat; product TD 88137, Harlan Teklad, 
Madison, WI) for an eight week intervention period while a control diet group remained on the 
chow food. Body weight was measured prior to the intervention and subsequent changes in 
mass were assessed on a weekly basis. Following the 8-week diet intervention, glucose and 
insulin tolerance tests were reassessed. The mice were sacrificed and tissue was collected one 
week after the final insulin tolerance test. Please refer to Figures 7.1 and 7.2 for experimental 
design details, and Appendices A and B for detailed diet information.  
 
Figure 7.1: Experimental Study Timeline (GTT: glucose tolerance test; ITT: insulin tolerance 




Figure 7.2: Experimental Study Design (HFD: high-fat diet; basal: vehicle injection pre-tissue 
collection; insulin: intraperitoneal injection of insulin pre-tissue collection; WT: wild-type 




7.3 Glucose and Insulin Tolerance Tests 
 Glucose tolerance testing was performed following an overnight fast (16 hours) for 
both high-fat and chow fed animals. Venous blood samples (6 μL) were drawn from the tail 
and assessed for glucose using a blood glucometer (Accu-Chek Aviva, Roche Diagnostics) at 
0, 30, 60, and 120 minutes following a 1g/kg body weight intraperitoneal injection of 10% D-
glucose (Li et al., 2000). 
 Insulin tolerance testing was performed on both high-fat and chow fed animals one-
week following the glucose tolerance test. The animals were fasted for 4-hours prior to an 
intraperitoneal injection of insulin (Humulin, Eli Lilly, Toronto, CA) at a dose of 0.75U/kg 
body weight. Blood samples were drawn from the tail and assessed for glucose using a blood 
glucometer (Accu-Chek Aviva, Roche Diagnostics) at 0, 30, 60, and 120 minutes post injection 
(Li et al., 2000). 
 
7.4 Tissue Collection 
Upon completion of the 8-week high fat diet, the phosphorylation state of several key 
insulin signalling molecules in skeletal muscle was assessed as previously described (Fujii et 
al., 2004; Morino et al., 2008). Fasted (4-hours) KO mice and wildtype littermates (HFD and 
chow-fed mice) were anaesthetized using sodium pentobarbital (0.65 mg/kg body weight) and 
were subjected to an intraperitoneal injection of insulin (0.75 units/kg) or vehicle solution (Fig. 
7.2). Whole gastrocnemius muscle was excised from each leg 15-min post-injection and freeze 
clamped immediately using aluminum tongs pre-cooled in liquid nitrogen. Tissue samples 
were stored at -80
o
C until further analysis. Next, the epididymal/inguinal and retroperitoneal 
fat pads were surgically removed for determination of the adiposity index. 
 
7.5 Adiposity Index Calculation 
 The adiposity index was defined as the percentage that the epididymal/inguinal and 
retroperitoneal fat pads accounted for in relation to total body mass. The adiposity index was 
calculated as (Taylor and Phillips, 1996): 





7.6 Skeletal Muscle Homogenization 
Frozen tissue samples (100 mg) were homogenized in a buffer consisting of (mM): 50  
Tris-HCl, 1 EGTA, 1 EDTA, 1% Triton X-100, 50 NaF, 5 sodium pyrophosphate, 10 sodium 
β-glycerol phosphate, 2 DTT, 1 sodium orthovanadate , 1 PMSF, and 10 μg/mL each of 
aprotinin, leupeptin, and pepstatin A. Protein content for each sample was determined using the 
Lowry protein method, as modified by Schacterle and Pollock (Schacterle & Pollock, 1973). 
 
7.7 Immunoblotting 
Muscle homogenate (IRS1 antibodies: 25 μg; phosphor-IRS1 antibodies: 30 μg; Akt 
antibodies: 6 μg) was separated by SDS-PAGE protocols (Laemmli, 1970) and transferred to 
polyvinylidene fluoride membranes (Roche Diagnostics, Mannheim, Germany). The 
polyvinylidene fluoride membranes were blocked for 1 hour at room temperature in Tris-
buffered saline with a 5% skim milk suspension, and subsequently incubated overnight at 4
o
C 









clone 24.6.2; Millipore) IRS-





587F11; Cell Signaling) Akt. After washing, the membranes were incubated with horseradish 
peroxidise-conjugated anti-mouse or anti-rabbit secondary antibody (Santa Cruz 
Biotechnology) for 1 hour at room temperature.  The blots were detected with an enhanced 
chemiluminescence kit (Amersham Pharmacia Biotech) using a bio-imaging system and 
densitometric analysis performed using the GeneSnap software (Syngene). Densitometric 
analysis was normalized to a control sample that was loaded onto each individual membrane to 
account for inter-membrane variability. 
 
7.8 Statistical Analysis 
Two-way ANOVAs were used to assess differences in body weight, fat pad weight, and 
the adiposity index between KO and WT mice in both HFD and chow-fed groups. Three-way 
ANOVAs were utilized to investigate differences in phosphorylation states of IRS1 and Akt 
from Western blot analysis between KO and WT mice in both diet groups.  Furthermore, three-
way ANOVAs with repeated measures were used to detect differences between the glucose and 
insulin tolerance test data of KO and WT mice at pre- and post-diet time points for different 
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times (0, 30, 60 and 120 min) for both diet groups. The significance level was set at 0.05, and
 
when appropriate, a Newman-Keuls post hoc test was used to compare
 
specific means. Trends 
in results will be mentioned when the significance value is less than 0.15. All values are 
reported as means ± standard error (SE). Sample sizes for the body and fat pad weight(s), 
adiposity index, and glucose and insulin tolerance test reflect the total number of mice in the 





8.1 Body Weight 
 Prior to the HFD, there were no differences in body weight (Fig. 8.1) between KO and 
WT mice (p>0.05). Moreover, no significant weight gain was observed in chow fed mice 
throughout the study (p>0.05). The HFD fed KO mice weighed significantly more than HFD 
fed WT mice at all time points during the 8-week period (p<0.001). Similarly, the HFD fed KO 
mice weighed significantly more than the standard chow fed control mice at all time points 
(p<0.001). The HFD fed WT mice weighed significantly more than chow fed WT mice at all 

























Figure 8.1. Absolute Change in Body Weight during the course of the 8-week high-fat or 
chow-diet intervention. There was no difference between KO and WT mice pre-diet (p>0.05). 
There was no significant difference between post-diet chow-fed KO and WT mice. HFD fed 
KO and WT mice weighed significantly more than control mice (* p<0.01). Further, HFD fed 
KO weighed significantly more than HFD fed WT (# p<0.001). Values are means ± SE (n=12 

























8.2 Adiposity Measures 
 Ex vivo measures for differences in adiposity revealed a main effect in which KO mice 
had a significantly larger epididymal/inguinal fat pad weight than WT mice irrespective of diet 
(Fig. 8.2A) (p<0.05). Further, a main effect was observed where HFD fed mice (KO and WT 
combined) had a significantly greater epididymal/inguinal fat pad weight than standard chow 
fed mice (p<0.0001). It was also observed that the HFD fed KO and WT mice had significantly 
greater retroperitoneal fat pad weights (Fig. 8.2B) than their respective chow fed control mice 
(p<0.01). However, the HFD fed KO mice had a significantly greater retroperitoneal fat pad 
weight than the HFD WT mice (p<0.001). The calculation of the adiposity index (Fig. 8.3) 
revealed a main effect of genotype (KO > WT; p<0.05) and a main effect of diet (HFD > 
Chow; p<0.0001). There was no difference between chow fed KO and WT mice in 
epididymal/inguinal or retroperitoneal fat pad weights, or adiposity index (p>0.05). Adiposity 
index values for all mice were in line with previous reports regardless of diet (Taylor & 
Phillips, 1996). 
 
8.3 Glucose Tolerance Testing 
 Glucose tolerance testing of the standard chow fed mice showed no significant 
difference in plasma glucose measures at any time point tested (0, 30, 60, or 120 min) between 
KO and WT mice either pre or post the 8-week diet time period (Fig. 8.4; p>0.05). However, 
there was a main effect observed where post-HFD fed mice (Fig. 8.5) had elevated plasma 
glucose measures at all time points compared with pre-HFD fed mice (p<0.001). Additionally, 
post-HFD fed KO mice exhibited significantly higher plasma glucose levels at 30, 60, and 120 
minutes post glucose injection than post-HFD fed WT mice (p<0.001). Intraperitoneal 
injection of glucose caused a significant increase in plasma glucose concentration in both pre-







































































Figure 8.2. Adiposity measures for chow and HFD fed mice. (A) epididymal and inguinal 
fat pad weight; (B) retroperitoneal fat pad weight. (A) There is a main effect of genotype 
(KO > WT; p<0.05) and of diet (HFD > Chow; p<0.001). (B) * Significantly different than 
control (p<0.01). # Significantly different than HFD WT (p<0.001). Values are means ± SE 












































































Figure 8.4. Glucose tolerance test pre and post chow diet. There was a main effect of time 
(0<60<30 min; p<0.001). There were no significant differences observed in plasma glucose 
levels between pre- and post-chow fed mice, or SLN KO and WT mice (p>0.05). Values are 
means ± SE (n=12). 
 
Figure 8.3. Adiposity Index for chow and HFD fed mice. There is a main effect of genotype 
(KO > WT; p<0.05) and of diet (HFD > Chow; p<0.001). Values are means ± SE (n=12 for 
WT and KO control; n=15 for WT and KO HFD). 
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8.4 Insulin Tolerance Testing 
 There was a main effect of age noted in which the post-chow fed mice (KO and WT 
combined) had on average a greater absolute plasma glucose concentration (Fig. 8.6A) than 
pre-diet period mice (p<0.01). Nonetheless, there were no notable differences in absolute or 
relative (Fig. 8.6B) plasma glucose measures at any time point (0, 30, 60, or 120 minutes) 
during the insulin tolerance test between the standard chow fed KO or WT mice either pre- or 
post-diet period (p>0.05). There was no significant difference between KO and WT pre- or 
post-diet in the area under the curve (AUC; Fig. 8.7) for the absolute change in plasma glucose 
concentration during the insulin tolerance test (p>0.05). There was a main effect of time (0<30, 
60, and 120 min) following insulin injection (p<0.001). 
The HFD intervention resulted in a greater absolute fasting plasma glucose measure 
(Fig. 8.8A) for both post-HFD fed KO and WT mice compared to pre-HFD fed controls 
(p<0.001). Similarly, there was a main effect where on average the HFD fed mice (KO and WT 
combined) had an elevated absolute plasma glucose level during the course of the test than pre-
HFD and standard chow fed control mice (Fig. 8.8A; p<0.001). Additionally, the HFD elicited 
a main effect where the HFD-fed mice (KO and WT combined) had a lower relative change in 
the plasma glucose concentration (Fig. 8.8B) 30-minutes post-insulin compared to pre-HFD 
control mice (p<0.01). Interestingly, on average there was a higher plasma glucose 
concentration observed for the KO mice than the WT mice regardless of diet (Fig. 8.8A; 
p<0.05). However, there were no significant differences between KO and WT mice in the 
absolute or relative change of plasma glucose at any individual time point during the insulin 
tolerance test pre- or post-HFD (p>0.05). As seen with the chow fed mice, there were no 
significant differences between KO and WT pre- or post-diet in the AUC (Fig. 8.9) for the 
absolute change in plasma glucose concentration during the insulin tolerance test (p>0.05). 

























Figure 8.5. Glucose tolerance test pre and post high fat diet. There was a main effect of 
time (pre: 0<60<30 min; post: 0<120<60<30 min; p<0.001). High-fat fed mice had 
significantly greater plasma glucose levels at 30, 60, and 120 min than pre-diet mice (* 
p<0.001). HFD KO mice had greater plasma glucose levels at 30, 60, and 120 min than 
HFD WT mice following an intraperitoneal injection of glucose (# p<0.01). Values are 









Figure 8.6. Insulin tolerance test pre- and post-chow diet. (A) absolute plasma glucose 
measure; (B) relative change in plasma glucose. A main effect was observed where post-diet 
mice had an elevated absolute plasma glucose measure on average compared to pre-diet 
mice (p<0.01). No significant difference KO versus WT (p>0.05). Main effect of time (0 < 


























Figure 8.7. AUC for the insulin tolerance test pre- and post-chow diet. (A) absolute 
change in plasma glucose; (B) area under the curve (AUC). There were no significant 
differences observed in AUC between KO and WT mice pre- or post-chow diet 






























Figure 8.8. Insulin tolerance test pre- and post-HFD. (A) absolute plasma glucose 
measure; (B) relative change in plasma glucose. (A) Fasting glucose was greater post-
HFD (post KO > pre KO; post WT > pre WT) than pre-diet controls (p<0.001). There 
was a main effect of genotype (KO > WT; p<0.05) and of diet (HFD > Control; 
p<0.001). (B) There was a main effect of diet (HFD > Control; p<0.01) at the 30-min 
time point. There were no significant differences observed in plasma glucose levels 
(A) or (B) between KO and WT mice pre- or post-chow diet (p>0.05). Main effect of 

























Figure 8.9. AUC for the insulin tolerance test pre- and post-HFD. (A) absolute change in 
plasma glucose; (B) area under the curve (AUC). There were no significant differences 
observed in AUC between KO and WT mice pre- or post-HFD diet (p>0.05). Values are 




8.5 Western Blot Analysis 
8.5.1 IRS1 Analysis 
 There was a main effect observed where the insulin treatment (KO and WT combined) 
produced a notable increase in the ratio of phosphorylated IRS1 tyr
628
 to total IRS1 protein 
(Fig. 8.10) compared to vehicle treated mice (p<0.001). Upon further analysis the standard 
chow fed control mice (KO and WT) exhibited a greater tyr
628
 phosphorylation of IRS1 after 
insulin treatment than HFD fed mice (p<0.02). However, there were no significant differences 
between KO and WT mice in total IRS1 protein expression (Fig. 8.10B) or IRS1 phospho-
tyr
628
 (Fig. 8.10C) regardless of the treatment (p>0.05). 
 Analysis of ser
307
 phosphorylation of IRS1 (Fig. 8.11) revealed a main effect for diet 
where there was a greater phospho-ser
307
 to total IRS1 ratio in the HFD fed mice (KO and WT) 
compared to the standard chow fed mice (p<0.03). There were no differences between KO and 
WT mice pre- or post-HFD (p>0.05). All values (means ± SE) were expressed as a ratio of 
phospho-residue to total protein normalized to the corresponding control group. 
 
8.5.2 Akt Analysis 
 Western blot analysis of Akt ser
473
 phosphorylation (Fig. 8.12C) detected no effect of 
insulin treatment regardless of diet (p>0.05). There was a non-significant trend noted where the 
HFD fed mice (KO and WT) exhibited a slightly greater expression of total Akt protein (Fig. 
8.12B) than chow fed mice (p=0.08).  
 A small non-specific band was detected immediately below the expected Akt ser
473
 
phosphorylated band (~60 kDa) on the Western blots for the anti-Akt phosho-ser
473
 antibody 
(Fig. 8.12A). Analysis of the unidentified band was performed due to the observation that a 
band was detectable in all insulin treatment mice and was absent in all non-insulin treated 
mice. Moreover, densitometric analysis of the non-specific band (Fig. 8.13A) revealed a 
significant increase in band density upon insulin stimulation in all mice (KO and WT) 
compared to non-insulin treated mice (p<0.001). Closer examination exposed a non-significant 
trend  for a 48% and 35% decrease in the non-specific band density post-HFD in insulin treated 
WT and KO mice, respectively, as compared to insulin treated chow fed mice (Fig. 8.13B; 








Figure 8.10: Western blot analysis of IRS1 phospho-tyr
628
 pre- and post-HFD. (A) 
Western blot for anti-IRS phospho-tyr
628
; (B) total IRS1 expression; (C) phospho-
tyr
628
:total IRS. (B) There was no difference between KO and WT regardless of diet 
(p>0.05). (C) There was a main effect of insulin treatment (Ins > Non; p<0.001). * 
Significant difference compared to insulin treated Con (p<0.02). There was no difference 
between KO and WT. All values were normalized to the corresponding control group 
(means ± SE; tyr
628
: n=4/4 for Con WT; n=4/6 for Con KO; n=7/8 for HFD WT; n=6/6 
for HFD KO Non/Ins, respectively; total n=11 for Con WT; n=12 for Con KO; n=15 for 



















































































Figure 8.11. Western blot analysis of IRS1 phospho-ser
307
 pre- and post-HFD. (A) 




:total IRS. (B) There was a 
main effect of diet (HFD > Con; *p<0.03;). There was no difference between KO and WT 
(p>0.05). All values were expressed normalized to the corresponding control group 
(means ± SE; ser
307



















































Figure 8.12. Western blot analysis of Akt phospho-ser
473
 pre- and post-HFD. (A) Western 
blot for anti-Akt phospho-ser
473
; (B) total Akt protein expression; (C) phospho-
ser
473
:total Akt. (A) anti-Akt phospho-ser
473
 located at 60 kDa. There was a trend of diet 
where HFD fed mice exhibited a greater total Akt protein expression than chow fed mice 
(p=0.08). (C) No effect of insulin treatment (Non=Insulin) pre- or post-HFD (p>0.05). 
All values were normalized to the corresponding control group (means ± SE; n=6/5 for 










































































Figure 8.13. Western blot analysis of anti-Akt phospho-ser
473
 unidentified band pre- and 
post-HFD. (A) non-specific band of ~60 kDa; (B) insulin stimulated non-specific band 
pre- and post-HFD. (A) Main effect of insulin treatment (Ins>Non; p<0.001). (B) Main 
effect trend of diet (Con>HFD) following insulin stimulation (p=0.13). All values were 
normalized to the corresponding control group (means ± SE; n=6/5 for Con WT; n=6/6 





 The findings of the present study confirmed previous reports that KO mice are more 
susceptible to obesity and its related comorbidities than wildtype mice following an 8-week 
high fat diet (Sayer et al., 2008; Bal et al., 2009). More specifically, the current investigation 
found that SLN ablation predisposes the high-fat fed mice to greater gains in whole body and 
retroperitoneal fat pad weight, and more severe glucose intolerance than wildtype control mice 
as hypothesized. In contrast to the hypothesis, there was no difference in insulin sensitivity 
between KO and wildtype mice following the HFD treatment.  
In this study it was believed that the HFD intervention would lead to greater reductions 
in the phosphorylation of IRS1 tyr
628
 and Akt ser
473
, and a larger increase in IRS1 ser
307
 
phosphorylation in KO mice than control mice. Assessment of the insulin signalling cascade 
within skeletal muscle showed a reduction in the insulin stimulated phosphorylation of IRS1 
tyr
628
 with the expected corresponding increase in IRS1 ser
307
 phosphorylation in both KO and 
wildtype mice after the completion of the HFD. However, there was no difference between KO 
and wildtype mice which is in contrast to the hypotheses. Insulin treatment did not stimulate 
any measurable increase in Akt ser
473
 phosphorylation in either KO or control mice regardless 
of the diet intervention which may reflect technical problems with the assay or a limitation 
with intraperitoneal insulin injections (see 9.5 Limitations). The lack of difference in IRS1 
tyr
628
 phosphorylation between the genotypes suggests that the more pronounced glucose 
intolerance observed for the KO mice may be the result of an alternative abnormality within 
the glucose regulatory machinery of the KO mice. 
 
9.1 Assessment of whole body and fat pad weight(s) following an 8-week HFD 
 Following the completion of the 8-week HFD the KO mice displayed a greater 
susceptibility to obesity as SLN ablation lead to a 20% greater increase in weight gain than 
high-fat fed control mice which is similar to the weight gain disparity observed in traditional 
rodent models of obesity such as the Otsuka Long-Evans Tokushima fatty (OLETF) rat, and 
the Zucker Diabetic fatty (ZDF) rat (Shima et al., 1993; Etgen & Oldham, 2000; Zhoa et al., 
2008). The chronic weight gain was evident from the initial stages of the diet intervention as 
the KO mice gained significantly more weight at each time point starting with the first week of 
the diet. Upon closer examination ex vivo analysis of fat pad weights showcased the enhanced 
45 
 
lipogenic ability of the KO mice as the knockout mice had a larger adiposity index and fat pad 
weights, particularly the retroperitoneal fat pad, than wildtype mice. Interestingly, it appears 
that the disparity in energy balance between the genotypes is only evident in conjunction with 
the HFD as standard chow fed mice had no discrepancies in weight gain or adiposity. These 
findings raise an important issue concerning how expression of SLN can minimize the 
development of obesity. 
 Skeletal muscle has been suggested to be a principle contributor to basal metabolic rate 
(BMR) and therefore, total daily energy expenditure (Zurlo et al., 1990; Rolfe & Brown, 1997; 
Levine, 2003). There are several energy consuming processes found within muscle such as 
proton leak (i.e. UCP3), protein synthesis, the sodium-potassium pump, and SERCA; all of 
which contribute to the total energy expenditure of skeletal muscle (Rolfe & Brown, 1997). 
Findings from a recent study (Norris et al., 2009) suggest that the Ca
2+
 handling duties of 
SERCA may factor into the total energy expenditure of skeletal muscle to a greater extent than 
previously believed (Hasselbach & Oetliker, 1983; Clausen, Hardeveld, & Everts, 1991; Chinet 
et al., 1992; Dulloo, Decrouy, & Chinet, 1994). Directly inhibiting the Ca
2+
 pump with the 
highly specific SERCA inhibitor, cyclopiazonic acid (Goeger & Riley, 1989; Seidler et al., 
1989), lead to a 50% reduction of muscle oxygen consumption in both fast- and slow-twitch 
isolated whole muscle preparations during resting conditions (Norris et al., 2009). During 
periods of elevated physical activity the proportion of energy expenditure attributed to SERCA 
is proposed to further increase as the magnitude of the Ca
2+
-handling duties within the muscle 
cell intensifies (Zhang et al., 2006). Taken together these findings suggest an important role of 
SERCA in skeletal muscle energy expenditure, and thus, total daily energy expenditure. 
Potentially any alteration to the efficiency of Ca
2+
 pumping by SERCA would have 
dramatic implications on the energy consumption of skeletal muscle. It could be assumed that 
the presence of SLN would influence the energy demands of Ca
2+
 pumping. In support of this 
notion, the co-expression of SLN and SERCA pumps in reconstituted vesicles increases the 
amount of heat produced in parallel to lowering the accumulation of Ca
2+
 inside the vesicles 
(Smith et al., 2002; Mall et al., 2006) which indicates the presence of an inefficient, futile cycle 
of Ca
2+
 transport. In other words, SLN uncouples ATP hydrolysis from the Ca
2+
 transport of 
SERCA pumps (Bombardier et al., 2008). Similarly, soleus muscle from KO mice had an 
approximately 10% lower contribution of SERCA towards the total oxygen consumption (i.e. 
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energy consumption) of skeletal muscle than wildtype mice (unpublished). The influence of the 
SLN:SERCA relationship towards total skeletal muscle energy expenditure appears almost 
insignificant considering the small overall impact that SLN:SERCA would have in relation to 
whole body energy expenditure. However, Butler and Kozak (2010) described a scenario 
where a discrepancy of approximately 5% in daily energy expenditure could result in 10-gram 
difference in the body weight between mice over the course of only a few months, which is in 
fact quite similar to the results from the present investigation. In other words, even a small 
disparity in energy balance can result in significant changes to body composition. Therefore, 
under conditions of severe energy distress, such as the exposure to a HFD, the ATP-sparing 
effect that SLN ablation has will predispose mice to diet-induced obesity.  
 
9.2 Evaluation of glucose tolerance in KO mice 
 Standard chow fed KO mice maintained a regular glucose tolerance response to an 
intraperitoneal glucose load as previously described (Sayer et al., 2008). It is not until the mice 
are exposed to the HFD that a dramatic discrepancy in the glucose handling capabilities of the 
mice is observed. As expected, both the KO and wildtype mice exhibit a marked impairment in 
glucose tolerance following the HFD; however, the KO mice were severely more glucose 
intolerant than littermate controls at all time points during the 2-hour glucose tolerance test 
which suggests that SLN ablation has a role in glucose homeostasis. The OLETF and ob/ob 
rodent models of spontaneous obesity and diabetes all portray similar impairments in plasma 
glucose during a 2-hour glucose tolerance test as the HFD KO mice (Shima et al., 1993; Miller 
et al., 2008). 
 One possible explanation for the impaired glucose tolerance in the KO mice is that the 
energy imbalance and subsequent gain in adiposity, produced by the ablation of SLN, leads to 
an intracellular environment that obstructs the skeletal muscle GLUT4 mediated uptake of 
glucose from systemic circulation as described in typical cases of insulin resistance (Shulman, 
2000; Morino, Petersen, & Shulman, 2006). Interestingly, KO mice display elevated plasma 
NEFA (unpublished). Typically, the spillover of NEFAs from adipose tissue stores into 
circulation results in the accumulation of intramyocellular lipid derivates, such as DAGs and 
ceramides, which produce the onset of insulin resistance due to the reduced activation of the 
insulin signalling cascade (Morino, Petersen, & Shulman, 2006; Timmers, Schrauwen, & de 
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Vogel, 2007; Kraegen & Cooney, 2008). There is a subsequent decrease in the translocation of 
GLUT4 to the cell surface which dramatically reduces glucose uptake (Shulman, 2000; 
Kraegen & Cooney, 2008). These findings formed the basis for examining insulin signalling in 
skeletal muscle in HFD KO mice in the current study. 
  
9.3 Analysis of whole body insulin sensitivity in HFD fed KO mice 
 Unexpectedly, consumption of the HFD did not reduce the whole body insulin 
sensitivity in either KO or WT mice during the insulin tolerance test as measured by the AUC 
(Fig. 8.9). These results suggest that reductions in whole body insulin sensitivity may not be 
responsible for the observed glucose intolerance in either genotype. A common characteristic 
in the onset of T2DM is the continual deterioration in the ability of the peripheral tissues to 
adequately respond to insulin (Morino, Petersen, & Shulman, 2006; Karlsson & Zierath, 2007). 
Thus, it is surprising that the current study did not observe any impairment of insulin 
sensitivity in either HFD fed KO or WT mice. However, the insulin tolerance test is not 
without its limitations (Borai et al., 2007). The insulin tolerance test cannot decipher the site of 
the impairment in insulin action; namely, the test is unable to differentiate between hepatic or 
peripheral insulin resistance (Borai et al., 2007). Moreover, the increase of plasma 
catecholamine, glucagon, cortisol, and growth hormone levels is the classic physiological 
response to hypoglycaemia, all of which antagonize the insulin response and may disrupt the 
results of the tolerance test (Borai et al., 2007). Thus, recognizing the limitations of the insulin 
tolerance test it would still be plausible that skeletal muscle insulin sensitivity may be reduced 






9.4 Effect of the HFD on the insulin signalling pathway of KO skeletal muscle  
 9.4.1 Phosphorylation of IRS1 tyr
628
 
 In agreement with previous reports, the standard chow fed mice (KO and WT) 
exhibited an approximate 3-fold increase in IRS1 tyr
628
 phosphorylation upon insulin 
stimulation (Griffen et al., 1999; Samuel et al., 2004; Delibegovic et al., 2007; Prada et al., 
2009; Wang et al., 2009). Following the HFD there was a comparable reduction in the 





 phosphorylation post-HFD was reduced to a similar extent as 
previously seen in ob/ob and diet-induced obese C57Bl mice (Saad et al., 1992; Hong et al., 
2009; Prada et al., 2005; Prada et al., 2009).   
 The fact that IRS1 tyr
628
 phosphorylation is impaired after exposure to the HFD does 
support the notion that altered insulin signalling in skeletal muscle is contributing to the 
marked glucose intolerance in both KO and wildtype mice. It has been well documented that 
insufficient activation of IRS1 is associated with decreased PI3K recruitment, Akt 
phosphorylation, and GLUT4 mediated glucose uptake (Karlsson & Zierath, 2007).  
  
9.4.2 Phosphorylation of Akt ser
473
 
 The assessment of the downstream intermediate Akt did not present the expected 
results as insulin did not stimulate Akt ser
473
 phosphorylation in either the wildtype or KO 
mice pre- or post-HFD. It is possible that the timing of the insulin treatment and tissue 
collection was not optimal to capture the true physiological functionality of the Akt molecule. 
However, Morino et al. (2008) reported an 8-fold increase of Akt ser
473
 phosphorylation in 
chow fed wildtype C57Bl/6J mice 15-minutes post-intraperitoneal insulin injection; HFD-fed 
wildtype mice exhibited an approximate 60% decrease in Akt activation compared to controls 
(Morino et al., 2008).  
 The documentation associated with the anti-Akt phospho-ser
473
 antibody asserts that the 
phospho-ser
473
 densitometric band should be detected at approximately 60 kDa as a thick dark 
band. As aforementioned, analysis of this band revealed no effect of insulin on Akt ser
473
 
phosphorylation (Fig. 8.12C). However, a non-specific (unidentified) insulin sensitive band 
was located directly below the ser
473
 band on the Western blot for anti-Akt phospho-ser
473
 (Fig. 
8.12A). Densitometric analysis of the unidentified band showed a substantial increase in 
49 
 
phosphorylation following insulin stimulation in all mice tested pre- and post-HFD. In 
agreement with the literature, there was a 48% and 35% decrease in phosphorylation in HFD-
fed wildtype and KO mice, respectively, compared to insulin stimulated chow fed controls 
(Prada et al., 2005; Zhou et al., 2007; Morino et al., 2008). Besides the noticeable trend in the 
data there is no evidence to suggest that the unidentified band is in fact the phospho-ser
473
 band 
for Akt. It is reasonable to propose that the non-specific band may be a degraded fraction of 
Akt, or perhaps the band is simply an unidentified alternative molecule of similar structure to 
Akt phosphorylated at ser
473
. Nonetheless, it would be of interest to identify the structure of the 
molecule and determine whether the molecule is integral to insulin signalling in skeletal 
muscle. 
 
9.4.3 Phosphorylation of IRS1 ser
307
 
 The HFD initiated an approximate 2.6 fold increase in IRS1 ser
307
 phosphorylation than 
chow fed controls similar to previous accounts of HFD-induced ser
307
 phosphorylation (Prada 
et al., 2005; Adochio et al., 2009). However, there was no significant difference observed 
between the KO and wildtype mice. As the intramyocellular concentration of lipid metabolites 
(e.g. DAGs, ceramides) increases during obesity, there is a measurable increase in the 
activation of PKCθ which has been shown to have detrimental effects on the viability of the 
insulin signalling pathway (Ravichandran et al., 2000; Schmitz-Peiffer, 2000; Morino, 
Petersen, & Shulman, 2006).  Namely, PKCθ phosphorylates several serine residues on both 
the insulin receptor and IRS1 substrates (near the tyrosine binding domain) (Karasik et al., 
1990; Paz et al., 1997; Aguirre et al., 2002; Liu et al., 2004). The ensuing decrease in IR/IRS1 
binding prohibits the expected insulin-stimulated tyrosine phosphorylation of IRS1 and 
activation of downstream signalling intermediates (Morino, Petersen, & Shulman, 2006).  The 
consequence of the insulin resistance is a decrease in glucose uptake and the inability to 
effectively manage systemic glucose homeostasis (Morino, Petersen, & Shulman, 2006). The 
observed increase in IRS1 ser
307
 phosphorylation provides a plausible mechanism for the 
reduced phosphorylation of IRS1 tyr
628
 and related glucose intolerance in both KO and WT 
mice. The lack of difference in the degree of IRS1 activation post-HFD between the genotypes 





9.5 Proposed hypothesis for severe glucose intolerance in HFD fed KO mice 
Another possibility for the severe glucose intolerance observed in the HFD fed KO 
mice could originate from a deficiency in insulin secretion due to a malfunction in the insulin-
releasing machinery of the pancreas (Guillausseau et al., 2008). In healthy islets, β-cell 
depolarization initiates the rapid entry of extracellular Ca
2+
 into the β-cell which promotes the 
exocytosis of insulin containing vesicles to the cell surface for the release of insulin into 
circulation (MacDonald, Joseph, & Rorsman, 2005). Insulin release is discontinued upon 
cellular repolarization and Ca
2+
 uptake into the endoplasmic reticulum by SERCA2b and 
SERCA3 (Borge et al., 2002). Pancreatic β-cells possess a positive feedback loop where 
insulin acts on the β-cells to recruit IRS1 to directly interact and inhibit SERCA to prevent 
Ca
2+
 uptake and prolong insulin release (Borge et al., 2002). SLN, therefore, may play an 
intimate role in the maintenance of insulin release as SLN is a known inhibitor of SERCA Ca
2+
 
transport (Odermatt et al., 1998; Asahi et al., 2002; Smith et al., 2002), and SLN mRNA has 
been identified in high quantities in the pancreas (European Molecular Biology Laboratory-
European Bioinformatics Institute EMBL-EBI, 2010). Preliminary data on isolated β-cell islets 
from chow fed KO mice indicate that there is no difference in glucose-stimulated insulin 
secretion compared to control mice (unpublished data). This should not be surprising as the 
chow fed mice exhibit no measurable difference in glucose tolerance. Further investigation on 
islet insulin secretion from HFD fed mice is warranted as KO mice may be more susceptible to 
diet-induced insulin secretion deficiencies which could contribute to the onset of glucose 






 One of the limitations of the current investigation centers upon the use of the insulin 
tolerance test to assess the whole body insulin sensitivity of the mice. The insulin tolerance test 
is associated with several weaknesses (Borai et al., 2007); namely, the physiological response 
to the insulin-induced hypoglycaemia including an increase in plasma catecholamines, 
glucagon, cortisol, and growth hormone, all of which may interfere with the interpretation of 
the test (Borai et al., 2007). Moreover, the insulin tolerance test cannot differeniate between 
hepatic or skeletal muscle insulin resistance (Borai et al., 2007). The euglycemic-
hyperinsulinemic clamp is the gold standard method for assessing insulin resistance; however, 
clamp studies are expensive and require specialized expertise (DeFronzo, Tobin, & Andres, 
1979; Borai et al., 2007). Similarly, the concentration of the intraperitoneal injection of insulin 
may elicit a maximal insulin-induced glucose uptake and may mask potential differences in 
insulin sensitivity or activation of the insulin signalling pathway. A lower dose of insulin could 
expose discrepancies in the insulin sensitivity of the mice. 
 Several previous publications have incubated isolated muscle preparations with insulin 
instead of utilizing the intraperitoneal injection model (Alkhateeb et al., 2009; Mullen et al., 
2009). Incubating isolated muscle preparations allows for a tighter control of insulin dosage 
(i.e. direct delivery to the muscle), and also avoids the confounding whole body effects of 
insulin and hypoglycaemia as previously mentioned (Borai et al., 2007), and thus allowing for 
a direct assessment of the insulin signalling pathway. However, the model employed in the 
current investigation does provide a representation of the whole body physiological response of 
glucose handling and skeletal muscle insulin signalling in the KO mice. One technique to 
improve the current methodology would be to collect the muscle sample during an euglycemic-
hyperinsulinemic clamp, thus eliminating the insulin injection issues as well as providing 
information on skeletal muscle glucose disposal rate, and plasma concentrations of glucose and 
insulin (Adochio et al., 2009). 
 Another limitation of the present study was the lack of any measurable Akt ser
473
 
phosphorylation upon insulin stimulation. It is possible that the timing between the insulin 
injection and tissue collection was not optimal for detection of Akt ser
473
 phosphorylation. The 
current investigation did not assess the plasma glucose concentration at the 15-minute mark 
during the insulin tolerance test; therefore, it is not possible to confidently conclude that 
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GLUT4 translocation and glucose uptake were not stimulated at this time point. Nonetheless, 
Morino et al. (2008) observed an approximate 8-fold increase in Akt ser
473
 phosphorylation in 
chow fed mice 15-minutes post insulin injection. Perhaps the assessment of insulin signalling, 
specifically Akt phosphorylation, in a highly oxidative skeletal muscle such as red 
gastrocnemius muscle instead of the whole gastrocnemius muscle collected in the present study 
would elicit a greater response as red oxidative muscle is more susceptible to diet-induced 
insulin resistance than white non-oxidative muscle (Wilkes et al., 1998). Also, red skeletal 
muscle exhibits a greater expression of SLN than white skeletal muscle (Babu et al., 2007b); 
therefore, the effect of SLN may be more evident in oxidative tissue. 
 One of the major limitations in the present investigation was the lack of a direct 
measure of GLUT4 translocation or glucose uptake. Skeletal muscle is responsible for the 
majority of insulin-stimulated glucose disposal (DeFronzo et al., 1981; Shulman et al., 1990), it 
is possible that more pronounced glucose intolerance in the HFD fed KO mice originates from 




 The KO mice exhibited a greater HFD-induced increase in body and retroperitoneal fat 
pad weight, and displayed more pronounced glucose intolerance than HFD fed control mice. 
The insulin tolerance test did not reveal any measurable impairment of whole body insulin 
sensitivity in either KO or WT mice following the HFD. However, there was a significant 
reduction in the phosphorylation of IRS1 tyr
628
 in both HFD fed KO and WT mice. IRS1 ser
307
 
phosphorylation was increased in both genotypes after the completion of the 8-week HFD 
which suggests a plausible mechanism for the reduced IRS1 tyrosine phosphorylation. In 
contrast to the insulin tolerance test, the Western blot data suggests that there is similar 
impairment in the activation of the skeletal muscle insulin signalling pathway in both 
genotypes. However, the results do not clarify as to why the KO mice have a dramatically 
reduced response during the glucose tolerance test. 
 The HFD fed KO mouse model exhibits similar changes in weight gain, glucose 




 as the currently employed OLETF, 
ZDF, and ob/ob rodent models of diabetes (Saad et al., 1992; Shima et al., 1993; Etgen & 
Oldham, 2000; Prada et al., 2005; Miller et al., 2008; Zhoa et al., 2008; et al., 2009). Also, the 
blood profile of HFD fed KO mice (Bal et al., 2009) follows the typical disease progression for 
diet-induced obesity and diabetes (Alberti & Zimmet, 1998; Karlsson & Zierath, 2007). 
Therefore, the current investigation supports the notion that the HFD fed KO mouse is a viable 





11.0 FUTURE DIRECTIONS 
 The primary goal of future investigations on the KO mouse model should focus upon 
further characterizing the mouse as a suitable model for T2DM. Specifically, the 
intramyocellular lipid profile, and the functionality of GLUT4 vesicle translocation and 
glucose uptake should be assessed in the KO mice following consumption of a HFD since 
abnormalities of these measures are classic features of diabetes (Karlsson & Zierath, 2007). 
Additionally, examination of pancreatic β-cell, hepatic, and adipose tissue function following 
the HFD intervention may provide useful insight into the greater glucose intolerance observed 
in the KO mice. Furthermore, the greater gain in fat mass observed for the KO mice may lead 
to abnormalities in the regulation of various adipokines, particularly leptin, adiponectin and 
TNFα, which have been associated with obesity and impairments of glucose and fat oxidation, 
and glucose uptake in skeletal muscle (Dyck et al., 2006). 
KO mice have been shown to have a higher sub-maximal rate of oxygen consumption 
than wildtype mice during treadmill running (Norris et al., 2008). This disparity should also be 
exploited via free access to running wheels as SLN should exhibit a greater influence during 
periods of high SERCA activity, such as during physical activity (i.e. elevated contraction-
relaxation cycling in skeletal muscle). Chronic exposure to this environment may potentially 
exacerbate the differences in weight gain observed between HFD fed KO and control mice, 
which should result in significantly greater metabolism in the wildtype mice and hence even 
lower susceptibility to obesity compared to KO mice. 
Another avenue of interest to be examined is the overexpression of SLN in skeletal 
muscle and its influence on metabolic rate and diet-induced obesity. It will be important to 
determine the optimal level of SLN expression in skeletal muscle as overexpression may alter 
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